Lipocine Inc. Overview
Pro stress-test →Lipocine is a clinical-stage biopharmaceutical company developing oral pharmaceutical products for metabolic, endocrine, and neurological disorders using proprietary lipid-based drug delivery technology. The company's approach addresses poor bioavailability challenges and improves patient compliance through innovative oral formulations.
Strategic Profile
Pro stress-test →Lipocine leverages its proprietary Lipral/Hydroance platform to create oral versions of poorly bioavailable drugs, positioning itself in underserved therapeutic areas including testosterone replacement, NASH (non-alcoholic steatohepatitis), obesity management, and postpartum depression. The company has one FDA-approved product (TLANDO) and a robust pipeline of clinical-stage candidates with late-stage development momentum.
Competitive Landscape
Pro stress-test →Lipocine competes indirectly with major testosterone replacement therapies (Testim, Androgel by AbbVie) and NASH treatment developers. Its proprietary oral delivery approach differentiates it in underserved indications like postpartum depression where limited approved treatments exist. The postpartum depression market is emerging with limited competitors, though depression therapeutics companies like Sage Therapeutics (SAGE) have zuranolone approved for this indication.
Industry Context
Lipocine Inc. operates in Specialty Biopharmaceuticals - Oral Drug Delivery & Clinical-Stage Development.
Key facts
Founded: 1997 · Headquarters: Salt Lake City, Utah, United States · Employees: Unknown · Revenue: Minimal/Pre-commercial · Market cap: $16.67M